Fulgent Genetics EV/EBIT FLGT

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2017.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 2.1×; Apr 2023
9-year median: 3.1×
9-year range: 0.9× to 493×
Peer median: 29.3×

Fulgent Genetics has no meaningful EV/EBIT today: it made an operating loss of $122.3M over the last twelve months.

It was last meaningful in Apr 2023, at 2.1×.

On the days it had one over the last 9 years, its median was 3.1×, from 0.9× in Jan 2023 to 493× in Aug 2020.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	2.1×	0.9×	2.8×
2022	0.9×	0.9×	2.6×
2021	3.4×	2.7×	60.1×
2020	18.7×	14.3×	493×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	74.9×	74.9×	147×

Against its peers

Companies in Medical - Diagnostics & Research nearest Fulgent Genetics' size, closest first, today.

Company	EV/EBIT
FLGTFulgent Genetics	n/m
NRCNRC Health	38.8×
ICCCImmucell	14.2×
CDNACareDx	29.3×
VCYTVeracyte	27.2×
BLLNBillionToOne	107×
Peer median	29.3×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Fulgent Genetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.